Table 2.
Baseline clinical and demographic data of NEDA and ODA patients.
| Variable | NEDA (n = 50) | ODA (n = 30) | p |
|---|---|---|---|
| Age (years) | 42.2 (36.3–47.8) | 38.2 (28.3–46.5) | ns |
| Disease duration (years). Median (IQR) | 9.9 (5.9–16.7) | 7.7 (2.2–13.3) | ns |
| Sex (male/female) | 13/37 | 6/24 | ns |
| EDSS score. Median (IQR) | 1.5 (1.5–2.5) | 1.5 (1.5–3.0) | ns |
| MSSS score. Median (IQR) | 2.1 (1.2–4.5) | 2.4 (1.8–3.3) | ns |
| N. of previous relapses. Median (IQR) | 4 (2–5) | 4 (2–7) | ns |
| Patients with relapses in the previous year (Yes/No) | 28/22 | 22/8 | ns |
| N. of relapses in the previous year. Median (IQR) | 1 (0–1) | 1 (0–1) | ns |
| Time from the last relapse (months). Median (IQR) | 6.0 (3.0–9.7) | 4.5 (3.0–9.5) | ns |
| Patients with relapses in the previous 3 months (Yes/No) | 8/42 | 8/22 | ns |
| N. of T2 lesions. Median (IQR) | 18 (11–26) | 19 (11–37) | ns |
| Patients with Gd + enhancing lesions (Yes/No) | 10/40 | 14/16 | 0.02 |
| N. of Gd+ enhancing lesions. Median (IQR) | 0 (0–0) | 0 (0––2) | 0.006 |
| Treatment naïve/ Previously treated | 17/33 | 8/22 | ns |
| Previous treatments (FL/SL) | 25/8 | 20/2 | ns |
| Wash-out period (months). Median (IQR) | 2 (2–4) | 3.0 (1.7–5.5) | ns |
EDSS Expanded Disability Status Scale, Gd Gadolinium, FL first line drugs, IQR interquartile range, NEDA no evidence of disease activity, MSSS Multiple Sclerosis Severity Score, N. number, NS NOT significant, ODA ongoing disease activity, SL second line drugs.